No Data
No Data
HC Wainwright & Co. Reiterates Buy on Biomea Fusion, Maintains $40 Price Target
Oppenheimer Maintains Biomea Fusion(BMEA.US) With Buy Rating, Cuts Target Price to $10
Promising Potential of Biomea Fusion's Icovamenib Justifies Buy Rating
Analysts Are Bullish on These Healthcare Stocks: Biomea Fusion (BMEA), Eledon Pharmaceuticals (ELDN)
Biomea Fusion Announces Presentation of Icovamenib Preclinical, Clinical Data
Biomea Fusion Presents Promising Clinical Data on Icovamenib at ATTD 2025, Highlighting Its Potential as a Disease-Modifying Therapy for Type 2 Diabetes